Clinicopathological Value of p16 Expression in Colorectal Carcinoma
NCT ID: NCT07047482
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2025-05-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Significance of Cortactin Expression in Colorectal Adenocarcinomas
NCT05225870
PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact
NCT05692895
Evaluation of Tumor Budding In Colorectal Adenocarcinoma
NCT07003776
Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp
NCT05638542
Effect of Silymarin in Metastatic Colorectal Cancer Patients
NCT05631041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
p16 is tumor suppressor gene with a vital rule ; inactivation of p16 leads to tumor formation and progression.
50 Specimens will be collected from Pathology Department of Sohag University Hospital. Sufficient clinical and histopathological data will be attached for each case.
The previously processed formalin-fixed, paraffin-embedded tissue blocks will be used to get Hematoxylin \& Eosin stained sections to confirm the diagnosis and to detect the histopathological type, grade and stage of each tumor.
Another sliced tissue sections will be immunohistochemically stained with p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants
Fifty (50) cases of colorectal cancer will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.
Immunohistochemical staining
Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunohistochemical staining
Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Tissue blocks with sufficient material.
3. Specimens with sufficient clinical data.
Exclusion Criteria
2. Specimens with insufficient clinical data.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherry Raouf Azmy
Demonstrator of pathology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Sohag, Recruiting, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Sherry R Azmy, Demonstrator of pathology
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Magdy M Amin, Professor
Role: primary
Sherry R Azmy, Demonstrator of pathology
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-6-2MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.